BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Abbott Laboratories (ABT) CEO, Execs See Pay Cut; Pfizer Inc. (PFE)'s Chief Ian Read's Pay Triples First Year on Job


3/16/2012 7:22:48 AM

Abbott Laboratories (ABT) Chairman and Chief Executive Miles White received total compensation worth 6.1% less in 2011 compared with the year before as the stock portion of his awards decreased. Abbott's diverse portfolio had cushioned it from some of the problems facing other large drug makers, like patent expirations and generic competition. But its profits have declined in recent quarters as restructuring and acquisition charges masked revenue growth. White last year received compensation valued at $24 million, down from $25.6 million a year earlier. Much of White's compensation again came in the form of stock awards, which were worth about $9.8 million in 2011, according to a filing with the U.S. Securities and Exchange Commission.

Meanwhile, Pfizer (PFE) Inc. Chief Executive Officer Ian Read received a 44 percent raise in total compensation last year to $25 million in his new role as head of the world’s largest drugmaker, according to a regulatory filing.

See sources for more info.


Read at Wall Street Journal
Read at Chicago Business
Read at Business Week
Read at Reuters
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES